12 Feb 2009 09:00 AM
Enzon Discontinues Further Development Of RhMBL
Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) announced the discontinuation of the current recombinant human Mannose-Binding Lectin (rhMBL) clinical program, as it did not meet the criteria established for its continued development.
"As we previously demonstrated, Enzon maintains high standards for developing its important and novel compounds," said Jeffrey H. Buchalter, chairman and chief executive officer of Enzon. "While it did not achieve the strict criteria we set forth for this program, MBL may still be a very important target in managing infectious complications."
In 2005 Enzon acquired the rights to rhMBL from the Danish biotech company NatImmune. Enzon has studied rhMBL in Phase Ib studies for the prevention of severe infections in individuals with multiple myeloma or undergoing liver transplant with deficient levels of MBL.
About Enzon
Enzon Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the development, manufacturing, commercialization of important medicines for patients with cancer and other life-threatening conditions…
"As we previously demonstrated, Enzon maintains high standards for developing its important and novel compounds," said Jeffrey H. Buchalter, chairman and chief executive officer of Enzon. "While it did not achieve the strict criteria we set forth for this program, MBL may still be a very important target in managing infectious complications."
In 2005 Enzon acquired the rights to rhMBL from the Danish biotech company NatImmune. Enzon has studied rhMBL in Phase Ib studies for the prevention of severe infections in individuals with multiple myeloma or undergoing liver transplant with deficient levels of MBL.
About Enzon
Enzon Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the development, manufacturing, commercialization of important medicines for patients with cancer and other life-threatening conditions…
